Most Recent
A judge has rejected a bid by Toyota's finance arm to require group members in two class actions to register ahead of mediation to participate in any settlement arising from mediation in the cases.
Construction PRO
A judge has threatened to vacate the trial in Dexus’ case against Melbourne Airport operator APAC after all the defendants tried to file documents late, suggesting the lawyers may be hit with personal costs orders.
Construction PRO
German car hire company SIXT has attacked the Darwin International airport owner's construction of their lease contract in a $1.9 million spat over the appropriate formula for rent calculations, saying it was trying to have the "best of both worlds".
Construction PRO
Trial in a case by the Wilderness Society challenging Santos' plans for its Reindeer gas field kicked off Tuesday, with counsel for the activist group saying the energy giant needed to show it coud cover decommissioning costs.
A leading competition law barrister has been appointed as the federal government’s chief legal advisor, with the government’s kids social media ban and attacks on hate speech laws to be among her early challenges.
A judge has asked for more information on why he should approve $43.1 million in legal fees in a class action against AMP that settled for $120 million, calling the amount "extraordinary" and "troubling".
Construction PRO
Questioning of the first witness in Dexus' case against Melbourne Airport's operator was an hour in when trial was halted by the judge, who complained of flying by the seat of his pants, documentary evidence-wise.
Dairy giant a2 Milk has agreed to cough up $62 million to settle a consolidated shareholder class action over a 2021 guidance.
A judge has said he will not be able to decide all the suppression applications in the ACCC’s misuse of market power case against Mastercard ahead of trial, saying the court was facing an “unreasonable, if not oppressive” burden.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.